Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 11/2009

01-11-2009 | Review Article

Quality of Life in Glaucoma and Three Other Chronic Diseases

A Systematic Literature Review

Authors: Tim Mills, Simon K. Law, John Walt, Patricia Buchholz, Jan Hansen

Published in: Drugs & Aging | Issue 11/2009

Login to get access

Abstract

Chronic diseases have a long-term negative impact on quality of life (QOL). Decreased QOL is associated with increased financial burden on healthcare systems and society. However, few publications have investigated the impact of glaucoma on patients’ QOL in comparison with other chronic diseases observed in patients with similar demographic characteristics.
To this end, a systematic literature search to assess QOL in glaucoma and three other chronic diseases (osteoporosis, type 2 diabetes mellitus and dementia) was performed. A total of 146 publications were identified that reported QOL using six commonly used generic QOL instruments: 36-, 12- and 20-item Short-Form Health Surveys (SF-36, -12 and -20), EuroQoL (EQ-5D), Sickness Impact Profile (SIP) and the Health Utilities Index-Mark III (HUI-III). The publication breakdown was as follows: glaucoma (10%), osteoporosis (26%), diabetes (52%) and dementia (12%); one publication assessed QOL in glaucoma, diabetes and dementia.
QOL was affected to a similar or slightly lesser degree by glaucoma than by osteoporosis, diabetes or dementia. Among the publications reporting SF- 36, -12 and -20 evaluations, physical component scores were generally lower than mental component scores across all diseases. QOL was affected more in patients with glaucoma than in demographically matched non-glaucomatous controls according to SF-20 assessment. EQ-5D and SIP results showed that QOL decreased as the severity of glaucoma increased. Patients with glaucoma had the lowest scores on the SIP instrument, indicating better QOL than patients with osteoporosis or diabetes (no data were available on dementia). The HUI-III instrument identified poorer QOL in patients with dementia than other diseases, probably due to cognitive deficits. However, for some of the instruments, data were scarce, and interpretation of the results should be conservative.
Although there are limited published QOL studies in glaucoma, its impact on QOL appears to be broadly similar to that of other serious chronic diseases. Development of a QOL instrument that measures vision-specific and general health aspects would better document the impact of glaucoma on QOL and would facilitate comparisons with other chronic disease states.
Literature
1.
Ko Y, Coons SJ. Self-reported chronic conditions and EQ-5D index scores in the US adult population. Curr Med Res Opin 2006 Oct; 22(10): 2065–71PubMedCrossRef
2.
Saarni SI, Harkanen T, Sintonen H, et al. The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual Life Res 2006 Oct; 15(8): 1403–14PubMedCrossRef
3.
Gibson PR, Weston AR, Shann A, et al. Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn’s disease. J Gastroenterol Hepatol 2007 Aug; 22(8): 1306–12PubMedCrossRef
4.
Keranen T, Kaakkola S, Sotaniemi K, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003 Jan; 9(3): 163–8PubMedCrossRef
5.
Livingston G, Katona C, Roch B, et al. A dependency model for patients with Alzheimer’s disease: its validation and relationship to the costs of care: the LASER-AD Study. Curr Med Res Opin 2004 Jul; 20(7): 1007–16PubMedCrossRef
6.
Severn P, Fraser S, Finch T, et al. Which quality of life score is best for glaucoma patients and why? BMC Oph-thalmol 2008; 8: 2CrossRef
7.
Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006 Mar; 90(3): 262–7PubMedCrossRef
8.
Clinical epidemiology of glaucoma. In: Allingham RR, Damji K, Freedman S, et al., editors. Shield’s textbook of glaucoma. 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2005
9.
Mittmann N, Trakas K, Risebrough N, et al. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics 1999 Apr; 15(4): 369–76PubMedCrossRef
10.
Boisjoly H, Gresset J, Fontaine N, et al. The VF-14 index of functional visual impairment in candidates for a corneal graft. Am J Ophthalmol 1999 Jul; 128(1): 38–44PubMedCrossRef
11.
Cypel MC, Kasahara N, Atique D, et al. Quality of life in patients with glaucoma who live in a developing country. Int Ophthalmol 2004 Oct–Dec; 25(5-6): 267–72PubMedCrossRef
12.
Gordon MO, Kass MA. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol 1999 May; 117(5): 573–83PubMedCrossRef
13.
Javitt JC, Schiffman RM. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I. J Glaucoma 2000 Jun; 9(3): 224–34
14.
Nah YS, Seong GJ, Kim CY. Visual function and quality of life in Korean patients with glaucoma. Korean J Ophthalmol 2002 Dec; 16(2): 70–4PubMed
15.
Nesher R, Ticho U. Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: effect on the quality of life of glaucoma patients with drug-related side effects. Isr Med Assoc J 2003 Apr; 5(4): 260–3PubMed
16.
Parrish 2nd RK, Gedde SJ, Scott IU, et al. Visual function and quality of life among patients with glaucoma. Arch Ophthalmol 1997 Nov; 115(11): 1447–55PubMedCrossRef
17.
Wilson MR, Coleman AL, Yu F, et al. Functional status and well-being in patients with glaucoma as measured by the Medical Outcomes Study Short Form-36 questionnaire. Ophthalmology 1998 Nov; 105(11): 2112–6PubMedCrossRef
18.
Ferrer M, Pellise F, Escudero O, et al. Validation of a minimum outcome core set in the evaluation of patients with back pain. Spine 2006 May 20; 31(12): 1372–9; discussion 80PubMedCrossRef
19.
Adachi JD, Loannidis G, Berger C, et al. The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int 2001; 12(11): 903–8PubMedCrossRef
20.
Hall SE, Criddle RA, Comito TL, et al. A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporos Int 1999; 9(6): 508–15PubMedCrossRef
21.
Hallberg I, Rosenqvist AM, Kartous L, et al. Health-related quality of life after osteoporotic fractures. Osteoporos Int 2004 Oct; 15(10): 834–41PubMedCrossRef
22.
Lombardi Jr I, Oliveira LM, Monteiro CR, et al. Evaluation of physical capacity and quality of life in osteoporotic women. Osteoporos Int 2004 Jan; 15(1): 80–5PubMedCrossRef
23.
Badia X, Diez-Perez A, Alvarez-Sanz C, et al. Measuring quality of life in women with vertebral fractures due to osteoporosis: a comparison of the OQLQ and QUALEFFO. Qual Life Res 2001; 10(4): 307–17PubMedCrossRef
24.
Dolan P, Torgerson D, Kakarlapudi TK. Health-related quality of life of Colles’ fracture patients. Osteoporos Int 1999; 9(3): 196–9PubMedCrossRef
25.
Cranney A, Coyle D, Pham BA, et al. The psychometric properties of patient preferences in osteoporosis. J Rheumatol 2001; 28(1): 132–7PubMed
26.
Gabriel SE, Kneeland TS, Melton 3rd LJ, et al. Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? Med Decis Making 1999; 19(2): 141–8PubMedCrossRef
27.
Stoffel M, Wolf I, Ringel F, et al. Treatment of painful osteoporotic compression and burst fractures using kyphoplasty: a prospective observational design. J Neuro-surg Spine 2007; 6(4): 313–9CrossRef
28.
Tosteson AN, Gabriel SE, Kneeland TS, et al. Has the impact of hormone replacement therapy on health-related quality of life been undervalued? J Womens Health Gend Based Med 2000; 9(2): 119–30PubMedCrossRef
29.
Badia X, Prieto L, Roset M, et al. Development of a short osteoporosis quality of life questionnaire by equating items from two existing instruments. J Clin Epidemiol 2002; 55(1): 32–40PubMedCrossRef
30.
Cascella T, Musella T, Orio Jr F, et al. Effects of neri-dronate treatment in elderly women with osteoporosis [published erratum appears in J Endocrinol Invest 2005 May; 28 (5): IV]. J Endocrinol Invest 2005; 28(3): 202–8PubMed
31.
Chien MY, Yang RS, Tsauo JY. Home-based trunk-strengthening exercise for osteoporotic and osteopenic postmenopausal women without fracture: a pilot study [published erratum appears in Clin Rehabil 2005; 19 (5): 579]. Clin Rehabil 2005; 19(1): 28–36PubMedCrossRef
32.
Picavet HS, Hoeymans N. Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. Ann Rheum Dis 2004; 63(6): 723–9PubMedCrossRef
33.
Randell AG, Nguyen TV, Bhalerao N, et al. Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int 2000; 11(5): 460–6PubMedCrossRef
34.
Zoarski GH, Snow P, Olan WJ, et al. Percutaneous ver-tebroplasty for osteoporotic compression fractures: quantitative prospective evaluation of long-term outcomes. J Vasc Interv Radiol 2002; 13(2 Pt 1): 139–48PubMedCrossRef
35.
Pande I, Scott DL, O’Neill TW, et al. Quality of life, morbidity, and mortality after low trauma hip fracture in men. Ann Rheum Dis 2006 Jan; 65(1): 87–92PubMedCrossRef
36.
Papaioannou A, Joseph L, Ioannidis G, et al. Risk factors associated with incident clinical vertebral and non-vertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 2005 May; 16(5): 568–78PubMedCrossRef
37.
Becker S, Garoscio M, Meissner J, et al. Is there an indication for prophylactic balloon kyphoplasty? A pilot study. Clin Orthop Relat Res 2007 May; 458: 83–9PubMed
38.
Do HM, Kim BS, Marcellus ML, et al. Prospective analysis of clinical outcomes after percutaneous vertebroplasty for painful osteoporotic vertebral body fractures. AJNR Am J Neuroradiol 2005 Aug; 26(7): 1623–8PubMed
39.
Khanna AJ, Reinhardt MK, Togawa D, et al. Functional outcomes of kyphoplasty for the treatment of osteoporotic and osteolytic vertebral compression fractures. Osteoporos Int 2006; 17(6): 817–26PubMedCrossRef
40.
Kocyigit H, Gulseren S, Erol A, et al. The reliability and validity of the Turkish version of Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Clin Rheumatol 2003; 22(1): 18–23PubMedCrossRef
41.
Marquis P, Cialdella P, De la Loge C. Development and validation of a specific quality of life module in postmenopausal women with osteoporosis: the QUALIOST. Qual Life Res 2001; 10(6): 555–66PubMedCrossRef
42.
Nguyen HV, Ludwig S, Gelb D. Osteoporotic vertebral burst fractures with neurologic compromise. J Spinal Disord Tech 2003; 16(1): 10–9PubMedCrossRef
43.
Trief PM, Wade MJ, Pine D, et al. A comparison of health-related quality of life of elderly and younger insulin-treated adults with diabetes. Age Ageing 2003 Nov; 32(6): 613–8PubMedCrossRef
44.
Schlotz W, Ambery P, Syddall HE, et al. Specific associations of insulin resistance with impaired health-related quality of life in the Hertfordshire Cohort Study. Qual Life Res 2007 Apr; 16(3): 429–36PubMedCrossRef
45.
Chittleborough CR, Baldock KL, Taylor AW, et al. Health status assessed by the SF-36 along the diabetes continuum in an Australian population. Qual Life Res 2006 May; 15(4): 687–94PubMedCrossRef
46.
Hermann BP, Vickrey B, Hays RD, et al. A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Res 1996 Oct; 25(2): 113–8PubMedCrossRef
47.
Boye KS, Matza LS, Oglesby A, et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual Life Outcomes 2006; 4: 80CrossRef
48.
Currie CJ, Poole CD, Woehl A, et al. The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy. Diabetologia 2006 Oct; 49(10): 2272–80PubMedCrossRef
49.
Camacho F, Anderson RT, Bell RA, et al. Investigating correlates of health related quality of life in a low-income sample of patients with diabetes. Qual Life Res 2002 Dec; 11(8): 783–96PubMedCrossRef
50.
De Berardis G, Pellegrini F, Franciosi M, et al. Longitudinal assessment of quality of life in patients with type 2 diabetes and self-reported erectile dysfunction. Diabetes Care 2005; 28(11): 2637–43PubMedCrossRef
51.
Edelman D, Olsen MK, Dudley TK, et al. Impact of diabetes screening on quality of life. Diabetes Care 2002 Jun; 25(6): 1022–6PubMedCrossRef
52.
Goldney RD, Phillips PJ, Fisher LJ, et al. Diabetes, depression, and quality of life: a population study. Diabetes Care 2004 May; 27(5): 1066–70PubMedCrossRef
53.
Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005 Jul; 28(7): 1568–73PubMedCrossRef
54.
Johnson JA, Nowatzki TE, Coons SJ. Health-related quality of life of diabetic Pima Indians. Medical Care 1996; 34(2): 97–102PubMedCrossRef
55.
Tang WL, Wang YM, Du WM, et al. Assessment of quality of life and relevant factors in elderly diabetic patients in the Shanghai community. Pharmacoepidemiol Drug Saf 2006; 15(2): 123–30PubMedCrossRef
56.
Adriaanse MC, Snoek FJ, Dekker JM, et al. No substantial psychological impact of the diagnosis of type 2 diabetes following targeted population screening: The Hoorn Screening Study. Diabet Med 2004; 21(9): 992–8PubMedCrossRef
57.
Gulseren L, Gulseren S, Hekimsoy Z, et al. Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients. Arch Med Res 2005 Mar–Apr; 36(2): 159–65PubMedCrossRef
58.
Hartley LA. Functional health status of persons with diabetes in a nurse-managed clinic. Diabetes Educ 2002; 28(1): 106–14PubMedCrossRef
59.
Kaholokula JK, Haynes SN, Grandinetti A, et al. Ethnic differences in the relationship between depressive symptoms and health-related quality of life in people with type 2 diabetes. Ethn Health 2006; 11(1): 59–80PubMedCrossRef
60.
Linzer M, Pierce C, Lincoln E, et al. Preliminary validation of a patient-based self-assessment measure of severity of illness in type 2 diabetes: results from the pilot phase of the Veterans Health Study. J Ambul Care Manag 2005; 28(2): 167–76
61.
Martinez-Castelao A, Gorriz JL, Garcia-Lopez F, et al. Perceived health-related quality of life and comorbidity in diabetic patients starting dialysis (CALVIDIA study). J Nephrol 2004 Jul–Aug; 17(4): 544–51PubMed
62.
Rejeski WJ, Lang W, Neiberg RH, et al. Correlates of health-related quality of life in overweight and obese adults with type 2 diabetes. Obesity 2006; 14(5): 870–83PubMedCrossRef
63.
Thommasen HV, Berkowitz J, Thommasen AT, et al. Understanding relationships between diabetes mellitus and health-related quality of life in a rural community. Rural Remote Health 2005 Jul–Sep; 5(3): 441PubMed
64.
Klein BE, Klein R, Moss SE. Self-rated health and diabetes of long duration. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 1998; 21(2): 236–40
65.
Ohsawa I, Ishida T, Oshida Y, et al. Subjective health values of individuals with diabetes in Japan: comparison of utility values with the SF-36 scores. Diabetes Res Clin Pract 2003; 62(1): 9–16PubMedCrossRef
66.
Sedgwick JE, Pearce AJ, Gulliford MC. Evaluation of equity in diabetes health care in relation to African and Caribbean ethnicity. Ethn Health 2003; 8(2): 121–33PubMedCrossRef
67.
Smide B, Lukwale J, Msoka A, et al. Self-reported health and glycaemic control in Tanzanian and Swedish diabetic patients. J Adv Nurs 2002; 37(2): 182–91PubMedCrossRef
68.
Tapp RJ, Dunstan DW, Phillips P, et al. Association between impaired glucose metabolism and quality of life: results from the Australian Diabetes Obesity and Lifestyle Study. Diabetes Res Clin Pract 2006; 74(2): 154–61PubMedCrossRef
69.
Tilly KF, Belton AB, McLachlan JF. Continuous monitoring of health status outcomes: experience with a diabetes education program. Diabetes Educ 1995; 21(5): 413–9PubMedCrossRef
70.
Vinik AI, Zhang Q. Adding insulin glargine versus rosiglita-zone: health-related quality-of-life impact in type 2 diabetes [published erratum appears in Diabetes Care 2007 Jun; 30 (6): 1684]. Diabetes Care 2007; 30(4): 795–800PubMedCrossRef
71.
Ahroni JH, Boyko EJ. Responsiveness of the SF-36 among veterans with diabetes mellitus. J Diabetes Complications 2000; 14(1): 31–9PubMedCrossRef
72.
Claiborne N, Massaro E. Mental quality of life: an indicator of unmet needs in patients with diabetes. Soc Work Health Care 2000; 32(1): 25–43PubMedCrossRef
73.
Gulliford MC, Mahabir D. Relationship of health-related quality of life to symptom severity in diabetes mellitus: a study in Trinidad and Tobago. J Clin Epidemiol 1999; 52(8): 773–80PubMedCrossRef
74.
Hendra TJ, Taylor CD. A randomised trial of insulin on well-being and carer strain in elderly type 2 diabetic subjects. J Diabetes Complications 2004; 18(3): 148–54PubMedCrossRef
75.
Ibrahim IA, Beich J, Sidorov J, et al. Measuring outcomes of type 2 diabetes disease management program in an HMO setting. South Med J 2002; 95(1): 78–87PubMed
76.
Kuo HK, Jones RN, Milberg WP, et al. Effect of blood pressure and diabetes mellitus on cognitive and physical functions in older adults: a longitudinal analysis of the advanced cognitive training for independent and vital elderly cohort. J Am Geriatr Soc 2005 Jul; 53(7): 1154–61PubMedCrossRef
77.
Nerenz DR, Repasky DP, Whitehouse FW, et al. Ongoing assessment of health status in patients with diabetes mellitus. Med Care 1992; 30(5 Suppl.): MS112–24PubMedCrossRef
78.
Norholm V, Bech P. The WHO Quality of Life (WHO-QOL) Questionnaire: Danish validation study. Nord J Psychiatry 2001; 55(4): 229–35PubMedCrossRef
79.
Oka RK, Sanders MG. The impact of type 2 diabetes and peripheral arterial disease on quality of life. J Vasc Nurs 2005; 23(2): 61–6PubMedCrossRef
80.
Paschalides C, Wearden AJ, Dunkerley R, et al. The associations of anxiety, depression and personal illness representations with glycaemic control and health-related quality of life in patients with type 2 diabetes mellitus. J Psychosom Res 2004; 57(6): 557–64PubMedCrossRef
81.
Wee HL, Li SC, Cheung YB, et al. The influence of ethnicity on health-related quality of life in diabetes mellitus: a population-based, multiethnic study. J Diabetes Complications 2006; 20(3): 170–8PubMedCrossRef
82.
Weinberger M, Kirkman MS, Samsa GP, et al. The relationship between glycemic control and health-related quality of life in patients with non-insulin-dependent diabetes mellitus. Med Care 1994 Dec; 32(12): 1173–81PubMedCrossRef
83.
Patterson MB, Whitehouse PJ, Edland SD, et al. ADCS Prevention Instrument Project: quality of life assessment (QOL). Alzheimer Dis Assoc Disord 2006 Oct–Dec; 20(4 Suppl. 3): S179–90PubMedCrossRef
84.
Novella JL, Boyer F, Jochum C, et al. Health status in patients with Alzheimer’s disease: an investigation of inter-rater agreement. Qual Life Res 2006 Jun; 15(5): 811–9PubMedCrossRef
85.
Novella JL, Jochum C, Ankri J, et al. Measuring general health status in dementia: practical and methodological issues in using the SF-36. Aging (Milano) 2001 Oct; 13(5): 362–9
86.
Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA 2003 Oct 15; 290(15): 2015–22PubMedCrossRef
87.
Balkrishnan R, Bond JB, Byerly WG, et al. Medication-related predictors of health-related quality of life in glaucoma patients enrolled in a Medicare health maintenance organization. Am J Geriatr Pharmacother 2003 Dec; 1(2): 75–81PubMedCrossRef
88.
Bellantonio S, Fortinsky R, Prestwood K. How well are community-living women treated for osteoporosis after hip fracture? J Am Geriatr Soc 2001 Sep; 49(9): 1197–204PubMedCrossRef
89.
Brenneman SK, Barrett-Connor E, Sajjan S, et al. Impact of recent fracture on health-related quality of life in postmenopausal women. J Bone Miner Res 2006 Jun; 21(6): 809–16PubMedCrossRef
90.
Brodaty H, Kemp NM, Low LF. Characteristics of the GPCOG, a screening tool for cognitive impairment. Int J Geriatr Psychiatry 2004 Sep; 19(9): 870–4PubMedCrossRef
91.
Cherry JC, Moffatt TP, Rodriguez C, et al. Diabetes disease management program for an indigent population empowered by telemedicine technology. Diabetes Technol Ther 2002; 4(6): 783–91PubMedCrossRef
92.
Cockerill W, Lunt M, Silman AJ, et al. Health-related quality of life and radiographic vertebral fracture. Os-teoporos Int 2004 Feb; 15(2): 113–9CrossRef
93.
Jackson JC, Hart RP, Gordon SM, et al. Six-month neu-ropsychological outcome of medical intensive care unit patients. Crit Care Med 2003 Apr; 31(4): 1226–34PubMedCrossRef
94.
Johnson JA, Maddigan SL. Performance of the RAND-12 and SF-12 summary scores in type 2 diabetes. Qual Life Res 2004 Mar; 13(2): 449–56PubMedCrossRef
95.
Lange LJ, Piette JD. Personal models for diabetes in context and patients’ health status. J Behav Med 2006 Jun; 29(3): 239–53PubMedCrossRef
96.
Logtenberg SJ, van Ballegooie E, Israel-Bultman H, et al. Glycaemic control, health status and treatment satisfaction with continuous intraperitoneal insulin infusion. Neth J Med 2007 Feb; 65(2): 65–70PubMed
97.
McCollum M, Ellis SL, Regensteiner JG, et al. Minor depression and health status among US adults with diabetes mellitus. Am J Manag Care 2007 Feb; 13(2): 65–72PubMed
98.
McCollum M, Hansen LS, Lu L, et al. Gender differences in diabetes mellitus and effects on self-care activity. Gend Med 2005 Dec; 2(4): 246–54PubMedCrossRef
99.
Ng TP, Feng L, Chiam PC, et al. Psychiatric morbidity and acute hospitalization in elderly people. Int Psychogeriatr 2006 Dec; 18(4): 701–11PubMedCrossRef
100.
Nichols GA, Brown JB. Functional status before and after diagnosis of type 2 diabetes. Diabet Med 2004 Jul; 21(7): 793–7PubMedCrossRef
101.
Palussiere J, Berge J, Gangi A, et al. Clinical results of an open prospective study of a bis-GMA composite in percutaneous vertebral augmentation. Eur Spine J 2005 Dec; 14(10): 982–91PubMedCrossRef
102.
Piette JD, Wagner TH, Potter MB, et al. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care. Med Care 2004 Feb; 42(2): 102–9PubMedCrossRef
103.
Sundaram M, Kavookjian J, Patrick JH, et al. Quality of life, health status and clinical outcomes in type 2 diabetes patients. Qual Life Res 2007 Mar; 16(2): 165–77PubMedCrossRef
104.
Sherwood MB, Garcia-Siekavizza A, Meltzer MI, et al. Glaucoma’s impact on quality of life and its relation to clinical indicators: a pilot study. Ophthalmology 1998 Mar; 105(3): 561–6PubMedCrossRef
105.
Ahroni JH, Boyko EJ, Davignon DR, et al. The health and functional status of veterans with diabetes. Diabetes Care 1994 Apr; 17(4): 318–21PubMedCrossRef
106.
Glasgow RE, Ruggiero L, Eakin EG, et al. Quality of life and associated characteristics in a large national sample of adults with diabetes. Diabetes Care 1997 Apr; 20(4): 562–7PubMedCrossRef
107.
Hanninen J, Takala J, Keinanen-Kiukaanniemi S. Quality of life in NIDDM patients assessed with the SF-20 questionnaire. Diabetes Res Clin Pract 1998 Oct; 42(1): 17–27PubMedCrossRef
108.
Stover JC, Skelly AH, Holditch-Davis D, et al. Perceptions of health and their relationship to symptoms in African American women with type 2 diabetes. Appl Nurs Res 2001 May; 14(2): 72–80PubMedCrossRef
109.
Westaway MS, Rheeder P, Gumede T. The effect of type 2 diabetes mellitus on health-related quality of life (HRQOL). Curationis 2001 Mar; 24(1): 74–8PubMedCrossRef
110.
Westaway MS, Seager JR, Rheeder P, et al. The effects of social support on health, well-being and management of diabetes mellitus: a black South African perspective. Ethn Health 2005 Feb; 10(1): 73–89PubMedCrossRef
111.
Kobelt G, Jonsson B, Bergstrom A, et al. Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden. Acta Ophthalmol Scand 2006 Jun; 84(3): 363–71PubMedCrossRef
112.
Montemayor F, Sibley LM, Courtright P, et al. Contribution of multiple glaucoma medications to visual function and quality of life in patients with glaucoma. Can J Ophthalmol 2001 Dec; 36(7): 385–90PubMed
113.
Borgstrom F, Zethraeus N, Johnell O, et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 2006; 17(5): 637–50PubMedCrossRef
114.
Dhillon V, Hurst N, Hannan J, et al. Association of low general health status, measured prospectively by Euro-QoL EQ-5D, with osteoporosis, independent of a history of prior fracture. Osteoporos Int 2005 May; 16(5): 483–9PubMedCrossRef
115.
Guilera M, Fuentes M, Grifols M, et al. Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study. Osteoporos Int 2006; 17(5): 664–71PubMedCrossRef
116.
Jakob F, Marin F, Martin-Mola E, et al. Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). QJM 2006 Aug; 99(8): 531–43PubMedCrossRef
117.
Kumar K, Verma AK, Wilson J, et al. Vertebroplasty in osteoporotic spine fractures: a quality of life assessment. Can J Neurol Sci 2005 Nov; 32(4): 487–95PubMed
118.
Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 2000 Jul; 15(7): 1384–92PubMedCrossRef
119.
Bech P, Moses R, Gomis R. The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharma-cotherapy naive type 2 diabetes: a placebo-controlled, multicentre study. Qual Life Res 2003 Jun; 12(4): 413–25PubMedCrossRef
120.
Currie CJ, McEwan P, Peters JR, et al. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 2005 Sep–Oct; 8(5): 581–90PubMedCrossRef
121.
Koopmanschap M. Coping with type II diabetes: the patient’s perspective. Diabetologia 2002 Jul; 45(7): S18–22PubMed
122.
Lucioni C, Garancini MP, Massi-Benedetti M, et al. The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study. Treat Endocrinol 2003; 2(2): 121–33PubMedCrossRef
123.
Ragnarson Tennvall G, Apelqvist J. Health-related quality of life in patients with diabetes mellitus and foot ulcers. J Diabetes Complications 2000 Sep–Oct; 14(5): 235–41PubMedCrossRef
124.
Redekop WK, Koopmanschap MA, Stolk RP, et al. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002 Mar; 25(3): 458–63PubMedCrossRef
125.
Sakamaki H, Ikeda S, Ikegami N, et al. Measurement of HRQL using EQ-5D in patients with type 2 diabetes mellitus in Japan. Value Health 2006 Jan–Feb; 9(1): 47–53PubMedCrossRef
126.
Andersen CK, Wittrup-Jensen KU, Lolk A, et al. Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia. Health Qual Life Outcomes 2004; 2: 52PubMedCrossRef
127.
Ankri J, Beaufils B, Novella JL, et al. Use of the EQ-5D among patients suffering from dementia. J Clin Epidemiol 2003 Nov; 56(11): 1055–63PubMedCrossRef
128.
Bryan S, Hardyman W, Bentham P, et al. Proxy completion of EQ-5D in patients with dementia. Qual Life Res 2005 Feb; 14(1): 107–18PubMedCrossRef
129.
Coucill W, Bryan S, Bentham P, et al. EQ-5D in patients with dementia: an investigation of inter-rater agreement. Med Care 2001 Aug; 39(8): 760–71PubMedCrossRef
130.
Naglie G, Tomlinson G, Tansey C, et al. Utility-based quality of life measures in Alzheimer’s disease. Qual Life Res 2006 May; 15(4): 631–43PubMedCrossRef
131.
Selwood A, Thorgrimsen L, Orrell M. Quality of life in dementia — a one-year follow-up study. Int J Geriatr Psychiatry 2005 Mar; 20(3): 232–7PubMedCrossRef
132.
Serrano-Aguilar PG, Lopez-Bastida J, Yanes-Lopez V. Impact on health-related quality of life and perceived burden of informal caregivers of individuals with Alzheimer’s disease. Neuroepidemiology 2006; 27(3): 136–42PubMedCrossRef
133.
Thorgrimsen L, Selwood A, Spector A, et al. Whose quality of life is it anyway? The validity and reliability of the Quality of Life-Alzheimer’s Disease (QOL-AD) scale. Alzheimer Dis Assoc Disord 2003 Oct–Dec; 17(4): 201–8PubMedCrossRef
134.
Vogel A, Mortensen EL, Hasselbalch SG, et al. Patient versus informant reported quality of life in the earliest phases of Alzheimer’s disease. Int J Geriatr Psychiatry 2006 Dec; 21(12): 1132–8PubMedCrossRef
135.
Janz NK, Wren PA, Lichter PR, et al. Quality of life in newly diagnosed glaucoma patients: the Collaborative Initial Glaucoma Treatment Study. Ophthalmology 2001 May; 108(5): 887–97; discussion 98PubMedCrossRef
136.
Janz NK, Wren PA, Lichter PR, et al. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology 2001 Nov; 108(11): 1954–65PubMedCrossRef
137.
De Grauw WJ, van de Lisdonk EH, Behr RR, et al. The impact of type 2 diabetes mellitus on daily functioning. Fam Pract 1999 Apr; 16(2): 133–9PubMedCrossRef
138.
De Grauw WJ, van de Lisdonk EH, van Gerwen WH, et al. Insulin therapy in poorly controlled type 2 diabetic patients: does it affect quality of life? Br J Gen Pract 2001 Jul; 51(468): 527–32PubMed
139.
Mueller MJ, Salsich GB, Strube MJ. Functional limitations in patients with diabetes and transmetatarsal amputations. Phys Ther 1997 Sep; 77(9): 937–43PubMed
140.
Papaioannou A, Adachi JD, Winegard K, et al. Efficacy of home-based exercise for improving quality of life among elderly women with symptomatic osteoporosis-related vertebral fractures. Osteoporos Int 2003 Aug; 14(8): 677–82PubMedCrossRef
141.
Bowker SL, Pohar SL, Johnson JA. A cross-sectional study of health-related quality of life deficits in individuals with comorbid diabetes and cancer. Health Qual Life Outcomes 2006; 4: 17PubMedCrossRef
142.
Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002 Jul–Aug; 22(4): 340–9PubMed
143.
Maddigan SL, Feeny DH, Johnson JA. A comparison of the health utilities indices Mark 2 and Mark 3 in type 2 diabetes. Med Decis Making 2003 Nov–Dec; 23(6): 489–501PubMedCrossRef
144.
Maddigan SL, Feeny DH, Johnson JA. Construct validity of the RAND-12 and Health Utilities Index Mark 2 and 3 in type 2 diabetes. Qual Life Res 2004 Mar; 13(2): 435–48PubMedCrossRef
145.
Maddigan SL, Feeny DH, Johnson JA. Health-related quality of life deficits associated with diabetes and co-morbidities in a Canadian National Population Health Survey. Qual Life Res 2005 Jun; 14(5): 1311–20PubMedCrossRef
146.
Maddigan SL, Feeny DH, Majumdar SR, et al. Health Utilities Index Mark 3 demonstrated construct validity in a population-based sample with type 2 diabetes. J Clin Epidemiol 2006 May; 59(5): 472–7PubMedCrossRef
147.
Maddigan SL, Majumdar SR, Guirguis LM, et al. Improvements in patient-reported outcomes associated with an intervention to enhance quality of care for rural patients with type 2 diabetes: results of a controlled trial. Diabetes Care 2004 Jun; 27(6): 1306–12PubMedCrossRef
148.
Mo F, Morrison H, Choi BC, et al. Evaluation and measurement of health-related quality of life for individuals with diabetes mellitus by Health Utilities Index Mark 3 (HUI3) system. Scientific World Journal 2006; 6: 1412–23PubMedCrossRef
149.
Roberts VL, Stewart J, Issa M, et al. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidi-nedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2005 Oct; 27(10): 1535–47PubMedCrossRef
150.
Wexler DJ, Grant RW, Wittenberg E, et al. Correlates of health-related quality of life in type 2 diabetes. Diabeto-logia 2006 Jul; 49(7): 1489–97CrossRef
151.
Sawka AM, Thabane L, Papaioannou A, et al. Health Utilities Index 3 scores in osteoporosis compared to other chronic medical conditions: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos) [abstract no. SA455]. J Bone Miner Res 2004; 19 Suppl.: S180
152.
Sawka AM, Thabane L, Papaioannou A, et al. Health-related quality of life measurements in elderly Canadians with osteoporosis compared to other chronic medical conditions: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 2005 Dec; 16(12): 1836–40PubMedCrossRef
153.
Walsh JB, Cleall S, Fahrlejtner A, et al. Quality of life and back pain in the European Forsteo Observational Study-EFOS [abstract no. SU392]. J Bone Miner Res 2006; 21 (Suppl.): S305
154.
Neumann PJ, Sandberg EA, Araki SS, et al. A comparison of HUI2 and HUI3 utility scores in Alzheimer’s disease. Med Decis Making 2000 Oct–Dec; 20(4): 413–22PubMedCrossRef
155.
Carver DJ, Chapman CA, Thomas VS, et al. Validity and reliability of the Medical Outcomes Study Short Form-20 questionnaire as a measure of quality of life in elderly people living at home. Age Ageing 1999 Mar; 28(2): 169–74PubMedCrossRef
156.
Horsman J, Furlong W, Feeny D, et al. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes 2003; 1: 54PubMedCrossRef
157.
Espallargues M, Czoski-Murray CJ, Bansback NJ, et al. The impact of age-related macular degeneration on health status utility values. Invest Ophthalmol Vis Sci 2005 Nov; 46(11): 4016–23PubMedCrossRef
158.
Katz JN, Larson MG, Phillips CB, et al. Comparative measurement sensitivity of short and longer health status instruments. Med Care 1992 Oct; 30(10): 917–25PubMedCrossRef
159.
Neudert C, Wasner M, Borasio GD. Patients’ assessment of quality of life instruments: a randomised study of SIP, SF-36 and SEIQOL-DW in patients with amyo-trophic lateral sclerosis. J Neurol Sci 2001 Oct 15; 191(1-2): 103–9PubMedCrossRef
160.
Stucki G, Liang MH, Phillips C, et al. The Short Form-36 is preferable to the SIP as a generic health status measure in patients undergoing elective total hip arthroplasty. Arthritis Care Res 1995 Sep; 8(3): 174–81PubMedCrossRef
Metadata
Title
Quality of Life in Glaucoma and Three Other Chronic Diseases
A Systematic Literature Review
Authors
Tim Mills
Simon K. Law
John Walt
Patricia Buchholz
Jan Hansen
Publication date
01-11-2009
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 11/2009
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/11316830-000000000-00000

Other articles of this Issue 11/2009

Drugs & Aging 11/2009 Go to the issue

Adis Drug Evaluation

Cerebrolysin

Original Research Article

Health State Values during the First Year of Drug Treatment in Early-Stage Parkinson’s Disease

Original Research Article

Medication-Related Admissions in Older People

Review Article

Lipid-Lowering Therapy for the Primary Prevention of Cardiovascular Disease in the Elderly

Original Research Article

Effects of Potent Anticholinergics, Sedatives and Antipsychotics on Postoperative Mortality in Elderly Patients with Hip Fracture
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits